Clinical trials: Cetuximab
Recurrent Rectal Cancer
The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer
The study is a prospective, single-center, single-arm, two-cohort, phase II clinical trial. Patients aged 18 years or older who had pelvic recurrence rectal cancer with or without resectable distant metastasis, with treatment…
- Trial name
- TORCH-R (NCT05628038)
- Testing
- PD-1 antibody, Capecitabine, 5FU
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Fudan University
Advanced Cancer
Bevacizumab in Multiple Phase I Combinations
The goal of this clinical research study is to find the highest tolerable dose of Avastin™ that can be given in combination with 4 other study drug/drug combinations.
- Trial name
- NCT00543504
- Testing
- Bevacizumab, Sorafenib, Erlotinib
- Where
- United States
- Volunteers
- 343 people
- Sponsor
- M.D. Anderson Cancer Center
CRC
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer
This is a non-randomized, open-label, dose-escalation and dose-expansion phase I/II clinical study to evaluate the safety, tolerability, and efficacy of HCB101 in combination with Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in…
- Trial name
- NCT07204574
- Testing
- HCB101, Bevacizumab, Cetuximab (Erbitux)
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Chang Gung Memorial Hospital
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCC
This study is the first clinical study in PD-1 resistant patients with head and neck squamous cell carcinoma with drugs targeting EGFR signaling pathway combined with CDK4/6 inhibitors, which explores the new combination…
- Trial name
- NCT05721443
- Testing
- Dalpiciclib+cetuximab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Solid Tumor, Adult, NSCLC
Study to Evaluate D-1553 in Subjects With Solid Tumors
This is a phase 1/2, open label study of D-1553 single agent and combination treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with…
- Conditions
- Solid Tumor, Adult, NSCLC, CRC
- Trial name
- NCT04585035
- Testing
- D-1553, D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other
- Where
- 25 sites in United States, Australia and 2 more
- Volunteers
- 180 people
- Sponsor
- InventisBio Co., Ltd
Cancer
Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer
The purpose of this study is to compare the effects (good and bad) of chemoradiotherapy with or without Bevacizumab (Avastin). Chemoradiotherapy is the combination of chemotherapy (the drugs pemetrexed and cetuximab) and…
- Trial name
- NCT00703976
- Testing
- Bevacizumab, Cetuximab, Pemetrexed
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Pittsburgh
Colorectal Cancer
Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer
To assess the efficacy of FOLFOX4 in combination with cetuximab, weekly and FOLFOX4 in combination with cetuximab, biweekly.
- Trial name
- CORE 2 (NCT00479752)
- Testing
- FOLFOX4 (Oxaliplatin), Cetuximab
- Where
- 24 sites in Austria, Bosnia and Herzegovina and 11 more
- Volunteers
- 151 people
- Sponsor
- Central European Cooperative Oncology Group
Colorectal Cancer
Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer
This is an open-label, multicenter, randomized study to be conducted in Chinese patients with RAS and BRAF wild-type mCRC. Patients who have already completed 9 cycles of standard first-line induction treatment, without…
- Trial name
- C-CLASSIC (NCT04262635)
- Testing
- Cetuximab, Capecitabine, Cetuximab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC
This is a single-center, single-arm, phase II clinical study to evaluate the efficacy and safety of PD-1 inhibitor combined with cetuximab in neoadjuvant therapy for locally advanced HNSCC.
- Trial name
- PC-1 (NCT05993858)
- Testing
- 3cycles (Toripalimab + cetuximab), Surgery, Radiotherapy or chemoradiotherapy
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Colorectal Cancer
Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy
Participants with metastatic Colorectal Cancer (mCRC) who have progressed on a prior Anti-epidermal growth factor receptor (EGFR) regimen randomized to receive IMC-A12 monotherapy or combination therapy with cetuximab to assess…
- Trial name
- NCT00503685
- Testing
- IMC-A12, cetuximab
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer, Colorectal Adenocarcinoma
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
Doctors leading this study hope to learn about the safety of combining the study drug VS-6766 with another drug called cetuximab in colorectal cancer.
- Conditions
- Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Advanced Colorectal Carcinoma
- Trial name
- NCT05200442
- Testing
- VS-6766/avutometinib, Cetuximab, Pill Diary
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Chicago
Colon Cancer, Rectal Cancer
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
The purpose of this study is to determine the value of adding IMC-A12 to irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC).
- Trial name
- FC-4 (NCT00845039)
- Testing
- Cetuximab, Irinotecan, IMC-A12 (cixutumumab)
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Eli Lilly and Company
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma
This phase II trial studies how well radiation therapy and cisplatin with or without cetuximab works in treating patients with human papillomavirus (HPV) positive, KRAS-variant stage III-IV oropharyngeal squamous cell carcinoma.
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, KRAS Protein Variant, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Trial name
- NCT04106362
- Testing
- Cetuximab, Cisplatin, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Advanced Non-Small Cell Lung Cancer
CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer
The purpose of this study is to select the more promising method of combining cetuximab with gemcitabine for treating patients with advanced non small-cell lung cancer, who are not candidates for platinum based therapy.
- Trial name
- CALC-1 (NCT00330746)
- Testing
- cetuximab, gemcitabine
- Where
- 25 sites in Italy
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute, Naples
Neoplasm Malignant, Colon Cancer Stage 4
Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study
This prospective Phase II study aims to evaluate the efficacy and safety of a modified FOLFOXIRI regimen in the treatment of metastatic colorectal cancer (MCRC).
- Trial name
- NCT06575127
- Testing
- FOLFOXIRI Protocol
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Al-Azhar University
Head and Neck, Squamous Cell Cancer
Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
The purpose of this study is to find out what effects, good and/or bad, 2 doses of Cetuximab will have on head and neck cancer. The study is done because 250 mg/m2 given weekly does not work very well.
- Trial name
- NCT00661427
- Testing
- cetuximab
- Where
- 17 sites in United States
- Volunteers
- 61 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV
Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN
This multicentre, randomised Phase II Pilot Study evaluates the efficacy of docetaxel, cisplatin and 5-fluorouracil or Cetuximab, followed by Cetuximab with radiotherapy.
- Conditions
- Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV, Squamous Cell Carcinoma of the Larynx Stage III, Squamous Cell Carcinoma of the Larynx Stage IV
- Trial name
- HNO-2 (NCT01884259)
- Testing
- Docetaxel, Cisplatin, 5-fluorouracil
- Where
- 8 sites in Austria
- Volunteers
- 100 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Metastatic Colorectal Cancer
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are…
- Trial name
- NCT04929223
- Testing
- Inavolisib, Bevacizumab, Cetuximab
- Where
- 84 sites in United States, Australia and 9 more
- Volunteers
- 542 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck
A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer
This is a phase 1/2, multi-center study with an open-label, dose escalation phase followed by a single-arm expansion phase to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 alone and in…
- Conditions
- Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck, Colorectal Adenocarcinoma, Metastatic Solid Tumor
- Trial name
- NCT04474470
- Testing
- NT219, NT219 and ERBITUX® - Dose Escalation, NT219 and ERBITUX® - Expansion
- Where
- 10 sites in United States, Israel
- Volunteers
- 52 people
- Sponsor
- TyrNovo Ltd.
Colorectal Cancer, Metastatic Cancer
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- ERBIFORT (NCT00557102)
- Testing
- cetuximab, filgrastim, fluorouracil
- Where
- France
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute, France
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.